Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23405650 | 1.00 | CHRM2 (0.45) | CHRM2CHRM4CHRM5OPRK1L3MBTL1 | |
| SCHEMBL12219688 | 1.00 | CHRM2 (0.45) | CHRM2CHRM4CHRM5OPRK1L3MBTL1 | |
| SCHEMBL21462353 | 1.00 | CHRM2 (0.45) | CHRM2CHRM4CHRM5OPRK1L3MBTL1 | |
| SCHEMBL2841484 | 0.86 | CHRM2 (0.49) | CHRM2CHRM4CHRM5OPRK1L3MBTL1 | |
| SCHEMBL2841486 | 0.86 | CHRM2 (0.49) | CHRM2CHRM4CHRM5OPRK1L3MBTL1 | |
| SCHEMBL4477292 | 0.86 | CHRM2 (0.49) | CHRM2CHRM4CHRM5OPRK1L3MBTL1 | |
| SCHEMBL12193988 | 0.84 | CHRM2 (0.42) | CHRM2CHRM4CHRM5OPRK1L3MBTL1 | |
| SCHEMBL16237890 | 0.84 | CHRM2 (0.44) | CHRM2CHRM4CHRM5OPRK1L3MBTL1 | |
| SCHEMBL636999 | 0.82 | CHRM2 (0.58) | CHRM2CHRM4CHRM5L3MBTL1KMT2A | |
| SCHEMBL16237639 | 0.79 | GRM6 (0.52) | CHRM2CHRM4CHRM5OPRK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729127-A2 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042776-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12486285-B2 | BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-12-02 | — | — | US | disclosed |
| US-20230287003-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-14 | — | — | US | disclosed |
| EP-4201939-A1 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2023-06-28 | — | — | EP | disclosed |
| EP-3774817-B1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2022-12-07 | — | — | EP | disclosed |
| US-11512095-B2 | BCL6 inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-11-29 | — | — | US | disclosed |
| US-20210163497-A1 | BCL6 INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163497-A1 | BCL6 INHIBITORS | BCL6, BCL6B, BCL3 | CHRM2 4751/4885CHRM4 4697/4885CHRM5 4734/4885 |
| US-20230287003-A1 | BCL6 INHIBITORS | BCL6, BCL6B, BCL3 | CHRM2 4751/4885CHRM4 4697/4885CHRM5 4734/4885 |
| US-12486285-B2 | BCL6 inhibitors | BCL6, BCL6B, BCL3 | CHRM2 4751/4885CHRM4 4697/4885CHRM5 4734/4885 |
| US-11512095-B2 | BCL6 inhibitors | BCL6, BCL6B, BCL3 | CHRM2 4751/4885CHRM4 4697/4885CHRM5 4734/4885 |
| US-20260042776-A1 | BCL6 INHIBITORS | BCL6, BCL6B, BCL9 | CHRM2 4733/4885CHRM4 4720/4885CHRM5 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.